Navigation Links
ACT Obtains Exclusive License for Hemangioblast Technology in North America
Date:7/21/2011

MARLBOROUGH, Mass., July 21, 2011 /PRNewswire/ -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it has entered into an agreement with CHA Bio & Diostech Co, Ltd. ("CHA Biotech"), a leading South Korea-based biotechnology company, designed to enhance the efforts of the two companies' international joint venture, Stem Cell & Regenerative Medicine International (SCRMI).  Under the terms of the agreement, SCRMI exclusively licenses the rights to its hemangioblast program to ACT for North America (United States and Canada) and to CHA Biotech for Korea and Japan.  Both companies will work to develop clinical therapies based on the joint venture's proprietary hemangioblast cell technology.  

Formed as a joint venture between ACT and CHA Biotech, SCRMI has been harnessing expertise from both sides of the globe in order to drive cutting-edge stem cell research endeavors.  Under the terms of the agreement, the SCRMI scientists involved in hemangioblast research have been reassigned to ACT where they will continue their research and product development efforts as ACT employees.  A total of 10 SCRMI employees are being reassigned to ACT, including Shi-Jiang (John) Lu, Ph.D., SCRMI's Senior Director of Research, Erin Kimbrel, Ph.D., Qiang (Allen) Feng, Ph.D., and their respective teams.  SCRMI's research has focused on differentiating human embryonic stem cells (hESCs) and induced pluripotent stem (iPS) cells into hemangioblasts - a multipotent cell that is a common precursor to blood, immune, and vascular tissue.  The ownership in SCMRI remains largely unchanged between ACT and CHA Biotech, with the joint venture ceasing internal research activity and transitioning to a licensing entity.

"The clinical prospects for this technology are immense," said Robert Lanza, M.D., chief scientific office
'/>"/>

SOURCE Advanced Cell Technology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
2. DuPont Obtains Biotechnology Endorsement for Pioneer(R) Brand Products
3. Occlutech Obtains Favourable Court Ruling in Patent Litigation in The Hague Against AGA Medical
4. China Sky One Medical, Inc. Obtains Production Rights for Nine New Drugs
5. NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies
6. Mindset BioPharmaceuticals (USA) Inc Obtains Notice of Allowance for European Patent Related to Use of Insulin Sensitizers in Senile Dementia, Dementia and Memory Loss
7. Sinovac Biotech Co. Ltd., Sinovacs Beijing Subsidiary, Obtains High-Tech Enterprise Status
8. Occlutech Obtains Favourable Ruling in Proceedings Initiated by AGA Medical
9. Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
10. China Sky One Medical, Inc. Obtains SFDA Approvals for Geranium Ointment and Musk Liniment for Pain Relief
11. SemBioSys Genetics Inc. obtains up to $1.5 million in funding from AVAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013 PuraMed BioScience ® , ... of over-the-counter (OTC) medicinal and healthcare products, announced ... the company based on low market capitalization valuation. ... All Natural Product to Treat Migraine Headaches ... Prescription Competitor , Currently Available Nationwide at ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 PI’s ... wide and provide 15 mm travel range with ... The small dimensions make these new positioners the ... spaces. A vacuum rated version is also available. ... specifications and datasheets can be found at: , ...
(Date:5/23/2013)... MENLO PARK, Calif. , May 23, 2013 /PRNewswire/ ... an oral treatment for pain has reached an important ... clinical trial of VBY-036 - a selective cathepsin S ... of VBY-036 is a double-blind, randomized, placebo-controlled study designed ... escalating doses of VBY-036 in healthy adults. ...
(Date:5/23/2013)... , May 23, 2013 Z Trim ... value-added ingredients to a variety of industries, announced that ... a panel discussion at this year,s National Restaurant Association ... 2013, on behalf of the Research Chefs Association.  Chef ... Restaurants: The Good, the Bad and the Ugly," joining ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3
... Selexis SA , a Swiss-based biotechnology company with ... yield and stable mammalian cell lines ... completed the sequencing of their proprietary Chinese hamster ovary ... project was performed in collaboration with the Institute ...
... Cell Technology, Inc. ("ACT"; OTC Bulletin Board: ... medicine, announced today that China,s State Intellectual Property Office ... broad intellectual property protection in China for the manufacturing ... from human embryonic stem cells (hESCs).   ...
... polymer solution equal the energy output and otherwise outperform platinum ... University engineers has found. The researchers are certain that ... the other advantages by matching the best nanotube layout and ... technique can knock down one of the major roadblocks to ...
Cached Biology Technology:Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome 2Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome 3Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome 4ACT to Be Issued Broad Patent for Human ES Cell-derived RPE Cells in China 2ACT to Be Issued Broad Patent for Human ES Cell-derived RPE Cells in China 3Cheap catalyst made easy 2
(Date:5/22/2013)... approach to genetic engineering drastically reduces the time ... bacteria, the workhorses of biotechnology, scientists are reporting. ... , the method paves the way for more ... environmental cleanup and other activities. , Keith Shearwin ... piece of the genetic material DNA into a ...
(Date:5/22/2013)... responsible for legionellosis, an infectious disease that can lead ... has developed a complex method enabling it to camouflage ... these acting against the infectious bacteria. , Research led ... which teams from the National Institute of Health (NIH) ... Barcelona (BSC) have also participated, has described for the ...
(Date:5/22/2013)... insects and wild plants have slowed in recent years, ... the University of Leeds and the Naturalis Biodiversity Centre ... in the diversity of species in Britain, Belgium and ... the picture brightened markedly after 1990, with a slowdown ... and wild plants. , Professor Bill Kunin, ...
Breaking Biology News(10 mins):Mechanism discovered which aids Legionella to camouflage itself in the organism 2Encouraging signs for bee biodiversity 2Encouraging signs for bee biodiversity 3
... An international team of researchers has studied the coralline algae ... Mediterranean Sea between 7.24 and 5.3 million years ago. Mediterranean ... following the isolation of the Mediterranean from the Indian Ocean ... The research team from the University of Granada ...
... Radiology 2009 Standards Division Guidelines" is the subject ... of the Journal of Vascular and Interventional ... and allied health professionals dedicated to improving public ... therapeutic interventionsprovides a unique collection of new (such ...
... from a one-of-a-kind, patient-driven effort to provide lung tissue ... idiopathic pulmonary fibrosis (IPF) are becoming dangerously ill and ... sustain them until life-saving transplants can be performed. ... of medicine, computational biology and pathology, and director of ...
Cached Biology News:Coralline algae in the Mediterranean lost their tropical element between 5 and 7 million years ago 2Journal of Vascular and Interventional Radiology: New patient radiation safety guidelines 2Journal of Vascular and Interventional Radiology: New patient radiation safety guidelines 3Pitt team first to profile genes in acutely ill idiopathic pulmonary fibrosis patients 2Pitt team first to profile genes in acutely ill idiopathic pulmonary fibrosis patients 3
This monoclonal antibody recognizes the light chain of human Factor XII and at 100 nM inhibits 50% of Factor XII activity. It may be used in ELISA to detect human Factor XII and in coagulation assay...
Chicken polyclonal to DCTD ( Abpromise for all tested applications). Antigen: Full length protein (Human) Entrez GeneID: 1635 Swiss Protein ID: P32321...
Mouse monoclonal [SPM325] to Xanthine Oxidase, prediluted ( Abpromise for all tested applications). Antigen: C terminal 358 amino acid fragment of human xanthine oxidase. Entrez Gene ID: 749...
Mouse monoclonal [2G1] to Vancomycin ( Abpromise for all tested applications)....
Biology Products: